Diabetic eye disease: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• VEGF 19
• GLP-1 1
• NRF2 0
• NLRP3 1
• AMPK 0
• AKT 0
• SGLT2 1
• HIF-1 0
• PPAR 0
• PI3K 0
• mTOR 0
• STAT3 0
• MAPK 0
• STING 0
• SIRT1 0
• ERK 0
• GPX4 0
• IL-1 0
• TLR4 0
• YAP 0
• ACE2 0
• CTNNB1 0
• HMGB1 0
• IL-6 1
• MMP-9 0
• TNF 0
• TP53 0
• ANGPTL3 0
• BDNF 0
• CXCR4 0
• FTO 0
• GIP 0
• HDAC 0
• IL-17 0
• JAK 0
• MEK 0
• PDGFR 0
• PINK1 0
• APOE 0
• AQP4 0
• BAP1 0
• BCL-2 0
• CCR5 0
• CD40 0
• CDK4/6 0
• CDKN2A 0
• COX-2 0
• DPP-4 0
• EGFR 0
• FAK 0
• G6PD 0
• IL-15 0
• IL-4 0
• JNK 0
• MDM2 0
• METTL3 0
• MYC 0
• NMDA 0
• RPGR 0
• TDP-43 0

EU-13 is a filter, not a ranking: it only narrows the list.

14 of 14+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting

  NCT06398080· Regeneron Pharmaceuticals· Updated 25 Nov 2024

  “Sponsor Decision”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns

  NCT06985706· Belfast Health and Social Care Trust· Source

• Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: Pain, Procedure Time, Patient Satisfaction, and Safety

  NCT07481500· Jakkrit Juhong· Source

• A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm

  NCT04503551· Hoffmann-La Roche· Source

• Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract Surgery

  NCT07301775· Ahmad Zeeshan Jamil· Source

• Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy

  NCT04278417· Novartis Pharmaceuticals· Source

• Effect of Video Viewing on Intravitreal Injection Experience

  NCT07002372· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Early Combined Use of Dexamethasone Intravitreal Implant and Anti-VEGF in the Treatment of DME.

  NCT06846073· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 15
• Organoids 2
• Mendelian Randomization Analysis 27
• CRISPR-Cas Systems 4
• Gene Expression Profiling 34
• Sequence Analysis, RNA 3
• Exome Sequencing 2
• Proteomics 30
• Metabolomics 15
• Mass Spectrometry 2
• Flow Cytometry 5
• Immunohistochemistry 13
• Liquid Biopsy 1
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 4
• Machine Learning 49
• Deep Learning 73
• Cohort Studies 47
• Genome-Wide Association Study 23

• [Modifiable risk factors and diabetic retinopathy: a Mendelian randomization analysis].

  Zhonghua Yan Ke Za Zhi, Nov 2026

• Liver-eye axis in metabolic syndrome: integrated evidence from mendelian randomization, single-cell sequencing, and clinical sample validation.

  Front Endocrinol (Lausanne), Sept 2026

• Multilevel genomic, transcriptomic, and epidemiologic evidence linking diabetic retinopathy to Alzheimer disease.

  J Glob Health, Sept 2026

• SGLT2 inhibitors and diabetic retinopathy progression: evidence from a retrospective cohort study and Mendelian randomization analysis.

  Front Endocrinol (Lausanne), Jul 2026

• Possible Causal Association Between Thyroid-Related Traits and Diabetic Retinopathy Risk: Evidence From 23 Medication-Taking Traits.

  Curr Eye Res, Jun 2026

• Causal association between systemic diseases and periodontitis: a two-way two-sample Mendelian randomization study.

  Quintessence Int, Jun 2026

• Shared Genetic Architectures and Causal Associations Between Diabetic Retinopathy Progression and Frailty-Related Phenotypes.

  Genes (Basel), May 2026

• HDGF as a Novel Serological Marker for Proliferative Diabetic Retinopathy: A Mendelian Randomization and Cross-Sectional Study.

  Transl Vis Sci Technol, May 2026

• Association between life course adiposity and diabetic microvascular complications: A univariable and multivariable Mendelian randomization study.

  Medicine (Baltimore), Apr 2026

• Causal relationship between hypertension and epilepsy mediated by diabetic retinopathy.

  Epilepsy Res, Mar 2026

See which targets of this disease your abstract mentions, and go to the people working on them.